BSECompany UpdateMgmt Change3d ago
GLAND PHARMA LIMITED
GLAND PHARMA LIMITED has informed BSE about Change in Directors/ Key Managerial Personnel/ Auditor/ Compliance Officer/ Share Transfer Agent.<p><b>Details are as under:</b></p>
<table width="100%" border="0" cellspacing="0" cellpadding="0">
<tbody>
<tr>
<td bgcolor="#d6d6d6"><table border="0" cellpadding="4" cellspacing="1" width="100%">
<tbody>
<tr><td width="250" class="TTRow_left"> </td><td class="TTRow_left"><b> Details</b></td></tr>
<tr><td ....
Gland Pharma Limited has informed BSE about the appointment of a Chief Investment Officer.
BSECompany UpdateMgmt Change3d ago
GLAND PHARMA LIMITED
GLAND PHARMA LIMITED has informed BSE about Change in Directors/ Key Managerial Personnel/ Auditor/ Compliance Officer/ Share Transfer Agent.<p><b>Details are as under:</b></p>
<table width="100%" border="0" cellspacing="0" cellpadding="0">
<tbody>
<tr>
<td bgcolor="#d6d6d6"><table border="0" cellpadding="4" cellspacing="1" width="100%">
<tbody>
<tr><td width="250" class="TTRow_left"> </td><td class="TTRow_left"><b> Details</b></td></tr>
<tr><td ....
GLAND PHARMA LIMITED has informed BSE about the appointment of a Chief Investment Officer.
BSECompany UpdateMgmt Change3d ago
Gland Pharma Ltd
Appointment of Mr. Xiao Le as Chief Investment Officer at Gland Pharma International Pte. Ltd, wholly owned subsidiary of Gland Pharma Limited, effective November 09, 2026
Gland Pharma Ltd has appointed Mr. Xiao Le as the Chief Investment Officer of its wholly-owned subsidiary Gland Pharma International Pte. Ltd, effective November 09, 2026. Mr. Xiao Le has over 15 years of experience in investment and assets management in the medical devices, biopharma, Dx/Tools, and healthcare services sectors.
BSECompany Update▼ NegativeResults3d ago
Silverline Technologies Ltd
Announcement under Regulation 30 (LODR)- Newspaper Publication
Silverline Technologies Ltd announces unaudited financial results for the quarter ended September 30, 2026, with net profit/loss for the period before tax at Rs. (49.83) lakhs, compared to Rs. (17.49) lakhs in the same quarter last year.
NSEAppointmentMgmt Change3d ago
Gland Pharma Limited
Appointment
Gland Pharma Limited has appointed Mr. Xiao Le as the Chief Investment Officer for its wholly-owned subsidiary, Gland Pharma International Pte. Ltd., effective November 09, 2026. Mr. Xiao Le will be responsible for exploring investment opportunities and improving M&A capability for Gland in the US, China, Singapore, and other countries.
NSEPress Release▲ PositiveResults3d ago
Shyam Metalics and Energy Limited
Press Release
Shyam Metalics and Energy Limited has reaffirmed its credit ratings from CRISIL, with a long-term rating of 'CRISIL AA+/Stable' and a short-term rating of 'CRISIL A1+'. The company's bank debt rating has been enhanced to ₹4,500 Crore, and its ₹50 Crore Commercial Paper programme has been reaffirmed at 'CRISIL A1+'.
NSECopy of Newspaper PublicationResults3d ago
Precision Wires India Limited
Copy of Newspaper Publication
Precision Wires India Limited has informed the Exchange about the publication of unaudited standalone financial results for the quarter and half-year ended September 30, 2026, in newspapers. Sagar Systech Limited has published a corrigendum to its unaudited financial results for the quarter ended September 30, 2026, due to an inadvertent clerical error. The company also announced the sale of immovable properties through e-auction.
BSECompany Update▲ PositiveResults3d ago
Shyam Metalics and Energy Ltd
Press Release issued regarding re-affirmation of Credit Rating dated 09th November, 2026
Shyam Metalics and Energy Ltd reaffirms its credit ratings with CRISIL, with the long-term rating at 'CRISIL AA+/Stable' and short-term rating at 'CRISIL A1+'. The company's bank debt rating has been enhanced to ₹4,500 Crore.
BSECompany Update▲ PositiveExpansion3d ago
Morepen Laboratories Ltd
Please find attached the Press Release
Morepen Laboratories Ltd has announced the launch of its first prescription (Rx) generic product, Desloratadine Tablets USP, in the U.S. market, building on its established API position. The company has also submitted its first Abbreviated New Drug Application (ANDA) to the U.S. FDA for Sitagliptin Phosphate Tablets USP. Morepen intends to pursue additional U.S. prescription generic filings and distribution opportunities.
NSEPress Release▲ PositiveExpansion3d ago
Morepen Laboratories Limited
Press Release
Morepen Laboratories Limited has announced the launch of its first prescription (Rx) generic product, Desloratadine Tablets USP, in the U.S. market, building on its established API position. The company has also submitted its first Abbreviated New Drug Application (ANDA) to the U.S. FDA for Sitagliptin Phosphate Tablets USP.
BSEBoard MeetingResults3d ago
Muzali Arts Ltd
Muzali Arts Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/11/2026 ,inter alia, to consider and approve the Unaudited Financial Results for the Second Quarter and Half Year Ended 30th September, 2026.
Muzali Arts Ltd has informed BSE that the meeting of the Board of Directors is scheduled on 14/11/2026 to consider and approve the Unaudited Financial Results for the Second Quarter and Half Year Ended 30th September, 2026.
BSECompany UpdateResults3d ago
GCM Capital Advisors Ltd
Please find attached Newspaper cuttings of publication of Unaudited Financial Results for HYE Sept 30, 2026
GCM Capital Advisors Ltd has announced the publication of unaudited financial results for the half year ended September 30, 2026. The results will be hosted on the company's website.
NSEUpdates▲ PositiveResults3d ago
BlueStone Jewellery and Lifestyle Limited
Updates
BlueStone Jewellery and Lifestyle Limited has reported a 45% YoY growth in Q3 FY27 (QTD) with a strong festive season performance, driven by buyer transactions and sustained consumer demand.
BSECompany Update▲ PositiveResults3d ago
BlueStone Jewellery and Lifestyle Ltd
Intimation of Business Update for the Festive Season
BlueStone Jewellery and Lifestyle Limited reports a 45% YoY growth in Q3 FY27 (QTD) with a solid festive season performance, driven by buyer transaction growth and improved momentum in product range across entry-level price points.
BSECompany UpdateResults3d ago
AMPL Capital Ltd
Enclosed herewith is the Newspaper Publication of Financials Results for the Quarter and Half Year Ended 30.09.2026
AMPL Capital Ltd has published its unaudited standalone and consolidated financial results for the quarter and half year ended 30.09.2026, as per Regulation 30 and 47(3) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
BSECompany UpdateResults3d ago
United Van Der Horst Ltd
Please find attached the copies of newspaper advertisement regarding completion of dispatch of Notice of Postal ballot to shareholders
United Van Der Horst Ltd has completed the dispatch of Notice of Postal Ballot to shareholders, as per the captioned subject, and has published the same in newspapers Active Times and Mumbai Lakshadeep.
BSECompany UpdateResults3d ago
United Van Der Horst Ltd
Pursuant to regulation 47 of SEBI (LODR) Regulation, 2015, please find enclosed herewith the extract copies of Newspaper advertisement clippings for Unaudited financial results of the Company for the quarter and half year ended 30th September, 2026
United Van Der Horst Ltd has announced the publication of its unaudited financial results for the quarter and half year ended September 30, 2026, as per Regulation 47 of SEBI (LODR) Regulation, 2015. The results are available on the company's website and the stock exchange's website.
BSEBoard MeetingResults3d ago
Arvaya Healthcare Ltd
Arvaya Healthcare Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 13/11/2026 ,inter alia, to consider and approve Pursuant to the provisions of Regulation 29(1) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please take note that the Meeting of the Board of Directors of the Company is scheduled to be held on Friday, November 13, 2026, to consider and approve, inter-alia, ....
Arvaya Healthcare Ltd has informed BSE that the meeting of the Board of Directors is scheduled on 13/11/2026 to consider and approve the Unaudited Standalone and Consolidated Financial Results for the Quarter and Half Year ended September 30, 2026.
NSEAnalysts/Institutional Investor Meet/Con. Call Updates▲ PositiveResults3d ago
Neogen Chemicals Limited
Analysts/Institutional Investor Meet/Con. Call Updates
Neogen Chemicals Limited has informed the Exchange about the Transcript of the Company’s Q2FY27 Earnings Conference Call held on November 2, 2026. The transcript highlights the company's robust all-round performance during the quarter, with consolidated revenue increasing by 42% year-on-year to INR 296 crore and EBITDA improving by 51% year-on-year to INR 45 crore. The company has also approved the expansion of manufacturing facility at Patancheru, Telangana, and successfully completed its maiden Qualified Institutional Placement (QIP) raising INR 600 crore.
BSECompany Update▲ PositiveResults3d ago
Neogen Chemicals Ltd
Earnings Call Transcript - Q2FY2027.
Neogen Chemicals Ltd reported a robust Q2FY27 performance with 42% year-on-year revenue growth to INR 296 crore and 51% year-on-year EBITDA growth to INR 45 crore. The company also announced the expansion of its Organolithium capacity at Patancheru and a successful Qualified Institutional Placement (QIP) raising INR 600 crore.